NCT00581750 observational |
Patients with lobular carcinoma in situ |
Tumor profiling |
Diagnosis |
October 2001 |
NCT01231386 observational |
Patients undergoing neoadjuvant or adjuvant chemotherapy and HT for locally advanced and inflammatory BC |
Tumor profiling, Circulating miRNAs |
Prognosis drug sensitivity |
October 2014 |
NCT01722851 observational |
Newly diagnosed BC patients who are scheduled to undergo neoadjuvant chemotherapy/HT and patients who present with disease recurrence or disease progression, and who are commenced on systemic therapies (HT and/or chemotherapy) |
Circulating miRNAs |
Prognosis drug sensitivity |
September 2013 |
NCT02656589 observational |
Patients with HER2+ advanced stage BC who were treated with herceptin |
Drug sensitivity |
June 2015 |
NCT01598285 observational |
Patients suffering from metastatic BC, treated with bevacizumab |
May 2012 |
NCT01612871 observational |
Patients with metastatic invasive BC or locally advanced BC for which treatment with tamoxifen or anti-aromatase is indicated |
June 2012 |